Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31-April 1, 2016, Tours, France

被引：27

作者：

Desoubeaux, Guillaume ^{[1
,2
,3
]}

Reichert, Janice M. ^{[4
,5
]}

Sleeman, Matthew ^{[6
]}

Reckamp, Karen L. ^{[7
]}

Ryffel, Bernhard ^{[8
,9
]}

Adamczewski, Joerg P. ^{[10
]}

Sweeney, Theresa D. ^{[11
]}

Vanbever, Rita ^{[12
]}

Diot, Patrice ^{[1
,2
,3
]}

Owen, Caroline A. ^{[13
,14
]}

Page, Clive ^{[15
]}

Lerondel, Stephanie ^{[16
]}

Le Pape, Alain ^{[1
,2
,16
]}

Heuze-Vourc'h, Nathalie ^{[1
,2
]}

机构：

[1] Univ Tours, Tours, France

[2] INSERM, Ctr Etud Pathol Resp, Tours, France

[3] Ctr Hosp Univ Tours, Tours, France

[4] Antibody Soc, Framingham, MA USA

[5] Reichert Biotechnol Consulting LLC, Framingham, MA USA

[6] MedImmune, Cambridge, England

[7] City Hope Natl Med Ctr, Ctr Comprehens Canc, Duarte, CA USA

[8] Univ Orleans, Orleans, France

[9] Univ Cape Town, Inst Infect Dis & Mol Med IDM, Cape Town, South Africa

[10] Sanofi R&D, Chilly Mazarin, France

[11] Nektar Therapeut, San Francisco, CA USA

[12] Catholic Univ Louvain, Louvain Drug Res Inst, Brussels, Belgium

[13] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA

[14] Lovelace Resp Res Inst, Albuquerque, NM USA

[15] Kings Coll London, Sackler Inst Pulm Pharmacol, London, England

[16] PHENOMIN TAAM CNRS, CIPA, Orleans, France

来源：

MABS | 2016年 / 8卷 / 06期

关键词：

Antibody therapeutics; animal models; innovation; infectious diseases; inhalation; respiratory diseases; CELL LUNG-CANCER; SYNCYTIAL VIRUS-INFECTION; 1ST-LINE THERAPY; CIGARETTE-SMOKE; OPEN-LABEL; BRONCHIAL HYPERRESPONSIVENESS; CONTROLLED PHASE-3; PLUS GEMCITABINE; AEROSOL THERAPY; INFLAMMATION;

D O I：

10.1080/19420862.2016.1196521

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Monoclonal antibody (mAb) therapeutics have tremendous potential to benefit patients with lung diseases, for which there remains substantial unmet medical need. To capture the current state of mAb research and development in the area of respiratory diseases, the Research Center of Respiratory Diseases (CEPR-INSERM U1100), the Laboratory of Excellence MAbImprove, the GDR 3260 Antibodies and therapeutic targeting, and the Grant Research program ARD2020 Biotherapeutics invited speakers from industry, academic and government organizations to present their recent research results at the Therapeutic Monoclonal Antibodies for Respiratory Diseases: Current challenges and perspectives congress held March 31 - April 1, 2016 in Tours, France.

引用

页码：999 / 1009

页数：11

共 60 条

[1] Inflammasome-IL-1-Th17 response in allergic lung inflammation [J].

Besnard, Anne-Gaelle ;

Togbe, Dieudonnee ;

Couillin, Isabelle ;

Tan, Zoming ;

Zheng, Song Guo ;

Erard, Francois ;

Le Bert, Marc ;

Quesniaux, Valerie ;

Ryffel, Bernhard .

JOURNAL OF MOLECULAR CELL BIOLOGY, 2012, 4 (01) :3-10

[2] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[3] The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquinolin-4-one] [J].

Boswell-Smith, Victoria ;

Spina, Domenico ;

Oxford, Alec W. ;

Comer, Mike B. ;

Seeds, Esther A. ;

Page, Clive P. .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 318 (02) :840-848

[4] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[5] The receptor NLRP3 is a transcriptional regulator of TH2 differentiation (vol 16, pg 859, 2015) [J].

Bruchard, Melanie ;

Rebe, Cedric ;

Derangere, Valentin ;

Togbe, Dieudonnee ;

Ryffel, Bernhard ;

Boidot, Romain ;

Humblin, Etienne ;

Hamman, Arlette ;

Chalmin, Fanny ;

Berger, Helene ;

Chevriaux, Angelique ;

Limagne, Emeric ;

Apetoh, Lionel ;

Vegran, Frederique ;

Ghiringhelli, Francois .

NATURE IMMUNOLOGY, 2015, 16 (12) :1292-1292

[6] Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation [J].

Cohen, E. Suzanne u ;

Scott, Ian C. ;

Majithiya, Jayesh B. ;

Rapley, Laura ;

Kemp, Benjamin P. ;

England, Elizabeth ;

Rees, D. Gareth ;

Overed-Sayer, Catherine L. ;

Woods, Joanne ;

Bond, Nicholas J. ;

Veyssier, Christel Seguy ;

Embrey, Kevin J. ;

Sims, Dorothy A. ;

Snaith, Michael R. ;

Vousden, Katherine A. ;

Strain, Martin D. ;

Chan, Denice T. Y. ;

Carmen, Sara ;

Huntington, Catherine E. ;

Flavell, Liz ;

Xu, Jianqing ;

Popovic, Bojana ;

Brightling, Christopher E. ;

Vaughan, Tristan J. ;

Butler, Robin ;

Lowe, David C. ;

Higazi, Daniel R. ;

Corkill, Dominic J. ;

May, Richard D. ;

Sleeman, Matthew A. ;

Mustelin, Tomas .

NATURE COMMUNICATIONS, 2015, 6

[7] Microdialysis in peripheral tissues [J].

de la Peña, A ;

Liu, P ;

Derendorf, H .

ADVANCED DRUG DELIVERY REVIEWS, 2000, 45 (2-3) :189-216

[8] Efficacy of aerosol therapy of lung cancer correlates with EGFR paralysis induced by AvidinOX-anchored biotinylated Cetuximab [J].

De Santis, Rita ;

Rosi, Antonio ;

Anastasi, Anna Maria ;

Chiapparino, Caterina ;

Albertoni, Claudio ;

Leoni, Barbara ;

Pelliccia, Angela ;

Santapaola, Daniela ;

Carollo, Valeria ;

Marra, Emanuele ;

Aurisicchio, Luigi ;

Arseni, Brunilde ;

Pacello, Maria Lucrezia ;

Palmieri, Gabriella ;

Battella, Simone ;

Petronzelli, Fiorella ;

Milazzo, Ferdinando Maria .

ONCOTARGET, 2014, 5 (19) :9239-9255

[9] Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection [J].

Detalle, Laurent ;

Stohr, Thomas ;

Palomo, Concepcion ;

Piedra, Pedro A. ;

Gilbert, Brian E. ;

Mas, Vicente ;

Millar, Andrena ;

Power, Ultan F. ;

Stortelers, Catelijne ;

Allosery, Koen ;

Melero, Jose A. ;

Depla, Erik .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (01) :6-13

[10] Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging [J].

Dijkers, Eli C. F. ;

Kosterink, Jos G. W. ;

Rademaker, Anna P. ;

Perk, Lars R. ;

van Dongen, Guus A. M. S. ;

Bart, Joost ;

de Jong, Johan R. ;

de Vries, Elisabeth G. E. ;

Lub-de Hooge, Marjolijn N. .

JOURNAL OF NUCLEAR MEDICINE, 2009, 50 (06) :974-981

← 1 2 3 4 5 6 →